NBIX 135.42 (+0.34%)
US64125C1099BiotechnologyBiotechnology

Neurocrine Biosciences (NBIX) Stock Highlights

135.42 | +0.34%
2024-12-21 01:00:15
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The companys three late stage clinical programs are elagolix which is hormone releasing antagonist for womens health, opicapone which is an inhibitor for parkinsons patients, and ingrezza for tourette syndrome.

Statistics

Range Today
134.12 137.01
Volume Today 1.92M
Range 1 Year
110.95 157.98
Volume 1 Year 221.03M
Range 3 Year
71.88 157.98
Volume 3 Year 604.53M
Range 10 Year
19.68 157.98
Volume 10 Year 2.26B

Highlights

Market Capitalization 12.73B (large)
Floating Shares 100.05M
Current Price 135.42
Price To Earnings 33.4
Price To Revenue 5.18
Price To Book 4.68
Earnings Per Share 3.74
Payout Ratio 0%

Performance

Latest +0.34%
1 Month +13.46%
3 Months +12.59%
6 Months +4%
1 Year +12.02%
3 Years +56.65%
5 Years +26.11%
10 Years +452.51%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.